Skip to main content

Table 1 Subtype of the breast cancer cell lines used in the experiments

From: Beta-hydroxybutyrate (3-OHB) can influence the energetic phenotype of breast cancer cells, but does not impact their proliferation and the response to chemotherapy or radiation

Cell line Receptor Subtype Ref. Mutations*
  ER PR Her2    
BT20 (−) np Basal A [60] ATM; BRCA2; CBLB; CDKN2A; COL1A1; RAP1GDS1; RB1; PIK3CA TP53
0 0 0–1 Basal [61]
BT474 + (+) + Luminal [60] EPS15; HIST1H3B; NSD1; PIK3CA; PPP2R1A; RHOA; TP53
0 8 3+ Luminal B [61]
+ +/− + Luminal B [59]  
HBL100 (−) np Basal B [60] np
MCF-7 + (+) np Luminal [60] ATP2B3; CDKN2A; EP300; ERBB4; MAP3K13; PIK3CA
6 6 0–1 Luminal A [61]
+ +/− Luminal A [59]
MDA-MB 231 (−) np Basal B [60] BRAF; CD79A; KRAS; CNKN2A; NF2; PBRM1; PDGFRA; TP53
0 0 0–1+ Basal [61]
MDA-MB 468 (−) (−) np Basal A [60] CACNA1D; INPP4B; PTEN; RB1; TP53
0 0 0 Basal [61]
Basal [59]
T47D + (+) np Luminal [60] ACVR1; ARID1A; PIK3CA; TP53
+ + Luminal A [59]
  1. The subtype of the breast cancer cell lines used was classified before by gene expression profile and the expression of the estrogen (ER), progesterone (PR), and human epidermal growth factor receptor 2 (Her2) receptor. The abbreviations of receptors and breast cancer subtype classification shown here are published [59,60,61]. Semiquantified receptor status: results with “−”, “(−)”, “0”, and “0–1+” are classified as negative and results with “+”, “(+)”, “+/−”, 6, and 8 are classified as positive for receptor expression (also summarized by [62])
  2. np not published
  3. *Mutations shown here are described by [63,64,65]